Article | Published:

ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer

Nature Medicine volume 22, pages 488496 (2016) | Download Citation

  • A Corrigendum to this article was published on 07 June 2016

This article has been updated

Abstract

The androgen receptor (AR) is overexpressed and hyperactivated in human castration-resistant prostate cancer (CRPC). However, the determinants of AR overexpression in CRPC are poorly defined. Here we show that retinoic acid receptor–related orphan receptor γ (ROR-γ) is overexpressed and amplified in metastatic CRPC tumors, and that ROR-γ drives AR expression in the tumors. ROR-γ recruits nuclear receptor coactivator 1 and 3 (NCOA1 and NCOA3, also known as SRC-1 and SRC-3) to an AR–ROR response element (RORE) to stimulate AR gene transcription. ROR-γ antagonists suppress the expression of both AR and its variant AR-V7 in prostate cancer (PCa) cell lines and tumors. ROR-γ antagonists also markedly diminish genome-wide AR binding, H3K27ac abundance and expression of the AR target gene network. Finally, ROR-γ antagonists suppressed tumor growth in multiple AR-expressing, but not AR-negative, xenograft PCa models, and they effectively sensitized CRPC tumors to enzalutamide, without overt toxicity, in mice. Taken together, these results establish ROR-γ as a key player in CRPC by acting upstream of AR and as a potential therapeutic target for advanced PCa.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Change history

  • 22 April 2016

    In Figure 2a of the version of this article initially published online, one phenyl ring was inadvertently deleted from the chemical structure of compound SR2211. One affiliation of H.-W.C. (Veterans Affairs Northern California Health Care System–Mather, Mather, California, USA) was also inadvertently omitted. These errors have been corrected for the print, PDF and HTML versions of this article.

Accessions

Primary accessions

Gene Expression Omnibus

Referenced accessions

Gene Expression Omnibus

References

  1. 1.

    , , , & Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects. Oncogene 34, 1745–1757 (2015).

  2. 2.

    et al. Understanding the mechanisms of androgen-deprivation resistance in prostate cancer at the molecular level. Eur. Urol. 67, 470–479 (2015).

  3. 3.

    , & Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat. Rev. Cancer 15, 701–711 (2015).

  4. 4.

    , & Molecular pathways: targeting resistance in the androgen receptor for therapeutic benefit. Clin. Cancer Res. 20, 791–798 (2014).

  5. 5.

    et al. An androgen receptor N-terminal domain antagonist for treating prostate cancer. J. Clin. Invest. 123, 2948–2960 (2013).

  6. 6.

    et al. New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells. Am. J. Pathol. 182, 460–473 (2013).

  7. 7.

    et al. Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer. Clin. Cancer Res. 20, 3198–3210 (2014).

  8. 8.

    et al. Galeterone prevents androgen receptor binding to chromatin and enhances degradation of mutant androgen receptor. Clin. Cancer Res. 20, 4075–4085 (2014).

  9. 9.

    et al. Targeting the MLL complex in castration-resistant prostate cancer. Nat. Med. 21, 344–352 (2015).

  10. 10.

    & REV-ERB and ROR nuclear receptors as drug targets. Nat. Rev. Drug Discov. 13, 197–216 (2014).

  11. 11.

    et al. Nuclear receptors rock around the clock. EMBO Rep. 15, 518–528 (2014).

  12. 12.

    , , & ROR nuclear receptors: structures, related diseases and drug discovery. Acta Pharmacol. Sin. 36, 71–87 (2015).

  13. 13.

    et al. Retinoic acid–related orphan receptor–γ (ROR-γ): a novel participant in the diurnal regulation of hepatic gluconeogenesis and insulin sensitivity. PLoS Genet. 10, e1004331 (2014).

  14. 14.

    et al. Isoform-specific amino-terminal domains dictate DNA-binding properties of ROR-α, a novel family of orphan hormone nuclear receptors. Genes Dev. 8, 538–553 (1994).

  15. 15.

    et al. Requirement for ROR-γ in thymocyte survival and lymphoid organ development. Science 288, 2369–2373 (2000).

  16. 16.

    & Estrogen-related receptors in breast cancer: control of cellular metabolism and beyond. Nat. Rev. Cancer 13, 27–36 (2013).

  17. 17.

    et al. Broad anti-tumor activity of a small molecule that selectively targets the Warburg effect and lipogenesis. Cancer Cell 28, 42–56 (2015).

  18. 18.

    et al. Integrative clinical genomics of advanced prostate cancer. Cell 161, 1215–1228 (2015).

  19. 19.

    et al. Identification of a selective ROR-γ ligand that suppresses TH17 cells and stimulates T regulatory cells. ACS Chem. Biol. 7, 1515–1519 (2012).

  20. 20.

    et al. Identification of SR2211: a potent synthetic ROR-γ–selective modulator. ACS Chem. Biol. 7, 672–677 (2012).

  21. 21.

    et al. Discovery of 2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide derivatives as new ROR-γ inhibitors using virtual screening, synthesis and biological evaluation. Eur. J. Med. Chem. 78, 431–441 (2014).

  22. 22.

    et al. Small-molecule ROR-γt antagonists inhibit TH17 cell transcriptional network by divergent mechanisms. Immunity 40, 477–489 (2014).

  23. 23.

    et al. Discovery of novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides as potent ROR-γt inhibitors. Bioorg. Med. Chem. 22, 692–702 (2014).

  24. 24.

    , , & Pharmacologic repression of retinoic acid receptor–related orphan nuclear receptor–γ is therapeutic in the collagen-induced arthritis experimental model. Arthritis Rheumatol. 66, 579–588 (2014).

  25. 25.

    et al. Identification of SR3335 (ML-176): a synthetic ROR-α–selective inverse agonist. ACS Chem. Biol. 6, 218–222 (2011).

  26. 26.

    et al. Genomic strategy for targeting therapy in castration-resistant prostate cancer. J. Clin. Oncol. 27, 2022–2029 (2009).

  27. 27.

    et al. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res. 72, 3457–3462 (2012).

  28. 28.

    et al. The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man. Cancer Cell 23, 35–47 (2013).

  29. 29.

    et al. CaM kinase kinase β–mediated activation of the growth regulatory kinase AMPK is required for androgen-dependent migration of prostate cancer cells. Cancer Res. 71, 528–537 (2011).

  30. 30.

    et al. Androgen-induced coactivator ANCCA mediates specific androgen receptor signaling in prostate cancer. Cancer Res. 69, 3339–3346 (2009).

  31. 31.

    et al. A validated regulatory network for TH17 cell specification. Cell 151, 289–303 (2012).

  32. 32.

    et al. Minor structural change to tertiary sulfonamide RORC ligands led to opposite mechanisms of action. ACS Med. Chem. Lett. 6, 276–281 (2015).

  33. 33.

    et al. Bufalin is a potent small-molecule inhibitor of the steroid receptor coactivators SRC-3 and SRC-1. Cancer Res. 74, 1506–1517 (2014).

  34. 34.

    et al. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature 510, 278–282 (2014).

  35. 35.

    et al. Aberrant presentation of HPA-reactive carbohydrates implies selectin-independent metastasis formation in human prostate cancer. Clin. Cancer Res. 20, 1791–1802 (2014).

  36. 36.

    et al. Adipogenesis and insulin sensitivity in obesity are regulated by retinoid-related orphan receptor gamma. EMBO Mol. Med. 3, 637–651 (2011).

  37. 37.

    et al. Androgen deprivation–induced NCoA2 promotes metastatic and castration-resistant prostate cancer. J. Clin. Invest. 124, 5013–5026 (2014).

  38. 38.

    et al. p300 acetyltransferase regulates androgen receptor degradation and PTEN-deficient prostate tumorigenesis. Cancer Res. 74, 1870–1880 (2014).

  39. 39.

    et al. Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer. Cancer Res. 66, 10594–10602 (2006).

  40. 40.

    et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 18, 11–22 (2010).

  41. 41.

    et al. The steroid receptor coactivator–3 is required for the development of castration-resistant prostate cancer. Cancer Res. 73, 3997–4008 (2013).

  42. 42.

    et al. The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J. Clin. Invest. 120, 4478–4492 (2010).

  43. 43.

    et al. LEF1 in androgen-independent prostate cancer: regulation of androgen receptor expression, prostate cancer growth and invasion. Cancer Res. 69, 3332–3338 (2009).

  44. 44.

    et al. NF-κB regulates androgen receptor expression and prostate cancer growth. Am. J. Pathol. 175, 489–499 (2009).

  45. 45.

    et al. Inhibition of androgen receptor and β-catenin activity in prostate cancer. Proc. Natl. Acad. Sci. USA 110, 15710–15715 (2013).

  46. 46.

    et al. An integrated network of androgen receptor, polycomb and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 17, 443–454 (2010).

  47. 47.

    et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N. Engl. J. Med. 371, 1028–1038 (2014).

  48. 48.

    et al. Interleukin-17 promotes formation and growth of prostate adenocarcinoma in mouse models. Cancer Res. 72, 2589–2599 (2012).

  49. 49.

    & Immune infiltration and prostate cancer. Front. Oncol. 5, 128 (2015).

  50. 50.

    , , , & Modeling truncated AR expression in a natural androgen-responsive environment and identification of RHOB as a direct transcriptional target. PLoS One 7, e49887 (2012).

  51. 51.

    et al. Histone methyltransferase NSD2 (MMSET) mediates constitutive NF-κB signaling for cancer cell proliferation, survival and tumor growth via a feed-forward loop. Mol. Cell. Biol. 32, 3121–3131 (2012).

  52. 52.

    et al. Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process. BMC Cancer 7, 64 (2007).

  53. 53.

    et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 487, 239–243 (2012).

  54. 54.

    et al. Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles. Cancer Res. 67, 5117–5125 (2007).

  55. 55.

    et al. Integration of copy number and transcriptomics provides risk stratification in prostate cancer: a discovery and validation cohort study. EBioMedicine 2, 1133–1144 (2015).

  56. 56.

    et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439, 353–357 (2006).

  57. 57.

    et al. ANCCA/ATAD2 overexpression identifies breast cancer patients with poor prognosis, acting to drive proliferation and survival of triple-negative cells through control of B-Myb and EZH2. Cancer Res. 70, 9402–9412 (2010).

  58. 58.

    et al. Reduced expression of mismatch repair genes measured by multiplex reverse transcription–polymerase chain reaction in human gliomas. Cancer Res. 57, 1673–1677 (1997).

  59. 59.

    & Fast and accurate short-read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754–1760 (2009).

  60. 60.

    , , & Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 10, R25 (2009).

  61. 61.

    et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat. Protoc. 7, 562–578 (2012).

  62. 62.

    et al. Transcript assembly and quantification by RNA-seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat. Biotechnol. 28, 511–515 (2010).

  63. 63.

    , , & Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. USA 95, 14863–14868 (1998).

  64. 64.

    et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545–15550 (2005).

  65. 65.

    et al. Androgen-induced recruitment of RNA polymerase II to a nuclear receptor–p160 coactivator complex. Proc. Natl. Acad. Sci. USA 100, 2226–2230 (2003).

  66. 66.

    et al. ChIP-seq: using high-throughput sequencing to discover protein-DNA interactions. Methods 48, 240–248 (2009).

  67. 67.

    & Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357–359 (2012).

  68. 68.

    et al. Model-based analysis of ChIP-seq (MACS). Genome Biol. 9, R137 (2008).

  69. 69.

    et al. Targeting autophagy overcomes enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model. Oncogene 33, 4521–4530 (2014).

Download references

Acknowledgements

We thank D. Wu, Q. Wang, D. Chen, F. Wu, F. Li, Y. He and J. Shen for their technical expertise and for their critical comments. We thank C. Sawyers and A. van Bokhoven for providing LAPC4 and PC346C cells. This work was supported in part by grants from the Bridge Program of the University of California, Davis, Research Office (to H.-W.C.); the US National Institutes of Health (NIH) (R01CA206222 to H.-W.C.); the US Department of Veterans Affairs; the Office of Biomedical Laboratory Research and Development Service (Merit Award I01BX002237 to H.-W.C.); the 100 Talents Projects of Chinese Academy of Sciences, the National Natural Science Foundation, the Guangzhou Healthcare Collaborative Innovation Programs and the Key Basic Research Program of China (grant 81373325, grant 20150820225 and 973 program grant 2013CB910601 to Y.X.); the Howard Hughes Medical Institute; the NIH (P30CA014195, DK057978, HL088093 and HL105278 to R.M.E.) and grants from Ipsen Biomeasure and the Samuel Waxman Cancer Research Foundation (to R.M.E.); the NIH (R01CA150197 and R01CA165263 to H.-J. K.); the US Department of Defense (PC111467 to C.P.E.) and a Stand Up To Cancer—Prostate Cancer Foundation—Prostate Dream Team Translational Cancer Research Grant. This research grant is made possible by the generous support of the Movember Foundation. Stand Up To Cancer is a program of the Entertainment Industry Foundation administered by the American Association for Cancer Research (SU2C-AACR-PCF DT0812 to C.P.E.) and the NIH (R01CA168601 to A.C.G.).

Author information

Affiliations

  1. Department of Biochemistry and Molecular Medicine, School of Medicine, University of California, Davis, Sacramento, California, USA.

    • Junjian Wang
    • , June X Zou
    • , Demin Cai
    • , Zhijian Duan
    • , Kit S Lam
    • , Hsing-Jien Kung
    •  & Hong-Wu Chen
  2. Institute of Chemical Biology, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.

    • Xiaoqian Xue
    • , Yan Zhang
    • , Qiuping Xiang
    •  & Yong Xu
  3. Department of Urology, School of Medicine, University of California, Davis, Sacramento, California, USA.

    • Joy C Yang
    • , Allen C Gao
    •  & Christopher P Evans
  4. Department of Natural Sciences and Mathematics, Dominican University of California, San Rafael, California, USA.

    • Maggie C Louie
  5. Department of Pathology and Laboratory Medicine, School of Medicine, University of California, Davis, Sacramento, California, USA.

    • Alexander D Borowsky
  6. Comprehensive Cancer Center, University of California, Davis, Sacramento, California, USA.

    • Allen C Gao
    • , Christopher P Evans
    • , Kit S Lam
    • , Hsing-Jien Kung
    •  & Hong-Wu Chen
  7. Shantou University Medical College, Shantou, China.

    • Jianzhen Xu
  8. Gene Expression Laboratory, Salk Institute, Howard Hughes Medical Institute, Salk Institute, La Jolla, California, USA.

    • Ronald M Evans
  9. Veterans Affairs Northern California Health Care System–Mather, Mather, California, USA.

    • Hong-Wu Chen

Authors

  1. Search for Junjian Wang in:

  2. Search for June X Zou in:

  3. Search for Xiaoqian Xue in:

  4. Search for Demin Cai in:

  5. Search for Yan Zhang in:

  6. Search for Zhijian Duan in:

  7. Search for Qiuping Xiang in:

  8. Search for Joy C Yang in:

  9. Search for Maggie C Louie in:

  10. Search for Alexander D Borowsky in:

  11. Search for Allen C Gao in:

  12. Search for Christopher P Evans in:

  13. Search for Kit S Lam in:

  14. Search for Jianzhen Xu in:

  15. Search for Hsing-Jien Kung in:

  16. Search for Ronald M Evans in:

  17. Search for Yong Xu in:

  18. Search for Hong-Wu Chen in:

Contributions

H.-W.C., J.W. and J.X.Z. conceived and initiated the research. H.-W.C., J.W., Y.X., R.M.E. and H.-J.K. designed the research. J.W., J.X.Z., X.X., D.C., Y.Z., Z.D., Q.X., J.C.Y. and M.C.L. performed the experiments. H.-W.C., J.W., J.X.Z., J.X., Y.X., M.C.L. and A.D.B. analyzed the data. H.-W.C., J.W., Y.X., A.C.G., C.P.E., K.S.L., H.J.K. and R.M.E. wrote and/or edited the manuscript.

Competing interests

H.W.C., J.X.Z., J.W. and Y.X. are co-inventors of a patent application covering methods of treating cancer with ROR-γ inhibitors. The other authors declare no competing financial interests.

Corresponding authors

Correspondence to Yong Xu or Hong-Wu Chen.

Supplementary information

PDF files

  1. 1.

    Supplementary Text and Figures

    Supplementary Figures 1–12 and Supplementary Tables 1–3

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/nm.4070

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing